AgeX Therapeutics (NYSE:AGE) Trading Down 11.9%

AgeX Therapeutics, Inc. (NYSE:AGE)’s stock price fell 11.9% during trading on Monday . The company traded as low as $11.10 and last traded at $11.10. 3,700 shares were traded during mid-day trading, a decline of 4% from the average session volume of 3,849 shares. The stock had previously closed at $12.60.

AgeX Therapeutics Stock Down 11.9 %

The company has a market cap of $11.99 million, a P/E ratio of -0.85 and a beta of 1.18. The business has a fifty day simple moving average of $3.45 and a two-hundred day simple moving average of $1.41.

Hedge Funds Weigh In On AgeX Therapeutics

A hedge fund recently raised its stake in AgeX Therapeutics stock. Sigma Planning Corp increased its position in shares of AgeX Therapeutics, Inc. (NYSE:AGE) by 57.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 286,425 shares of the company’s stock after purchasing an additional 105,040 shares during the period. Sigma Planning Corp owned 0.75% of AgeX Therapeutics worth $110,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.50% of the company’s stock.

AgeX Therapeutics Company Profile

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.